Combined targeting of the MAPK pathway along with inhibitors of STAT3 was suggested to counteract STAT3-mediated resistance phenotypes in human melanoma cells (Vultur et al., 2014).Thus, shikonin may be a valuable candidate along with the specific inhibitor(s) of MAPK pathways to enhance the efficiency of melanoma treatments. Here, STAT3 is linked to melanoma.